IPP Bureau
Merck KGaA to set up € 300 million Bioprocessing Production Center in South Korea
By IPP Bureau - May 30, 2024
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
By IPP Bureau - May 30, 2024
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Merck to acquire EyeBio for US$ 1.3 billion upfront payment
By IPP Bureau - May 30, 2024
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
By IPP Bureau - May 29, 2024
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Strides receives USFDA approval for Sucralfate oral suspension, 1gm/10 mL
By IPP Bureau - May 29, 2024
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
By IPP Bureau - May 29, 2024
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth
By IPP Bureau - May 29, 2024
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Bluecrux supports Sanofi in harnessing AI to transform supply chains
By IPP Bureau - May 28, 2024
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
Roche and Hitachi High-Tech extend partnership for further breakthroughs in diagnostic testing
By IPP Bureau - May 28, 2024
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Ascentage releases results from multiple clinical studies of its lead drug candidates
By IPP Bureau - May 28, 2024
These abstracts report on the company's three lead drug candidates, including olverembatinib
AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
By IPP Bureau - May 28, 2024
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
AstraZeneca furthers ambition to transform outcomes in early lung cancer at ASCO 2024
By IPP Bureau - May 27, 2024
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Alvotech and Dr. Reddy’s collaborate for commercialization of AVT03 (denosumab)
By IPP Bureau - May 27, 2024
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
AbbVie completes acquisition of Landos Biopharma
By IPP Bureau - May 27, 2024
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction
By IPP Bureau - May 27, 2024
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
